Claims
- 1. A compound of the formula: ##STR23## wherein R.sup.1 is hydrogen or halogen; and R.sup.2 is hydrogen, halogen, azido, an optionally substituted lower alkyl, an optionally substituted lower alkylcarbonyl, an optionally substituted arylcarbonyl, an optionally substituted heteroarylcarbonyl, --OR.sup.7 (wherein R.sup.7 is hydrogen, an optionally substituted lower alkyl, an optionally substituted lower alkylcarbonyl, an optionally substituted arylcarbonyl, an optionally substituted heteroarylcarbonyl, an optionally substituted lower alkylsulfonyl, an optionally substituted arylsulfonyl, an optionally substituted heteroarylsulfonyl, --SO.sub.3 H, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted carbamoyl, or --PO.sub.3 H.sub.2), S(O).sub.n R.sup.13 (wherein R.sup.13 is hydrogen, an optionally substituted lower alkyl, or an optionally substituted aryl, and n is 0, 1, or 2), or --NHR.sup.8 (wherein R.sup.8 is hydrogen, an optionally substituted lower alkyl, an optionally substituted lower alkylcarbonyl, an optionally substituted lower alkylsulfonyl, an optionally substituted arylcarbonyl, an optionally substituted aralkyloxycarbonyl, an optionally substituted arylsulfonyl, an optionally substituted heteroarylsulfonyl, or an optionally substituted carbamoyl); or R.sup.1 and R.sup.2 taken together may form oxo or .dbd.NR.sup.9 (wherein R.sup.9 is hydroxy, a lower alkoxy, an optionally substituted aralkyl, an optionally substituted arylsulfonylamino, or --NHCONH.sub.2);
- R.sup.3 is hydrogen or halogen; and R.sup.4 is hydrogen, halogen, --OR.sup.10 (wherein R.sup.10 is hydrogen, an optionally substituted lower alkyl, an optionally substituted lower alkylcarbonyl, an optionally substituted arylcarbonyl, an optionally substituted heteroarylcarbonyl, an optionally substituted lower alkylsulfonyl, an optionally substituted arylsulfonyl, an optionally substituted heteroarylsulfonyl, --SO.sub.3 H, or --PO.sub.3 H.sub.2), SR.sup.14 (wherein R.sup.14 is hydrogen, an optionally substituted lower alkyl, or an optionally substituted aryl), or --NHR.sup.11 (wherein R.sup.11 is hydrogen, an optionally substituted lower alkyl, an optionally substituted lower alkylcarbonyl, an optionally substituted lower alkylsulfonyl, an optionally substituted arylsulfonyl, an optionally substituted heteroarylsulfonyl, or an optionally substituted carbamoyl); or R.sup.3 and R.sup.4 taken together may form oxo or .dbd.NR.sup.12 (wherein R.sup.12 is hydroxy, cyano, amino, an optionally substituted lower alkoxy, an optionally substituted aralkyl, an optionally substituted arylsulfonylamino, an optionally substituted aliphatic heterocyclic group, or --NHCONH.sub.2); or R.sup.2 and R.sup.4 taken together may form an unsaturated bond or --O--;
- A is .dbd.NR.sup.5 (wherein R.sup.5 is hydrogen, lower alkyl, lower alkylcarbonyl, or lower alkylsulfonyl; or R.sup.5 and Z.sup.1 taken together may form an unsaturated bond);
- R.sup.6 is hydrogen, cyano, nitro, amino, halogen, an optionally substituted carboxy, or an optionally substituted carbamoyl;
- X is hydrogen, cyano, nitro, amino, halogen, hydroxy, lower alkoxy, an optionally substituted carboxy, an optionally substituted carbamoyl;
- Y.sup.1 and Y.sup.2 are both hydrogens, or taken together may form oxo;
- Z.sup.1 and Z.sup.2 are both hydrogens, or taken together may form oxo, or Z.sup.1 is hydrogen and Z.sup.2 is hydroxy, an optionally substituted lower alkyl, or an optionally substituted lower alkoxy, or an optionally substituted aryl),
- the pharmaceutically acceptable salt, or the hydrate thereof.
- 2. The compound of claim 1, wherein A is .dbd.NH; Z.sup.1 and Z.sup.2 are both hydrogens; Y.sup.1 and Y.sup.2 taken together form oxo.
- 3. The compound of claim 1, wherein R.sup.1 is hydrogen; R.sup.2 is hydrogen, halogen, amino, azido, or --OR.sup.7 (R.sup.7 is referred to as the same above); R.sup.3 is hydrogen, R.sup.4 is --OH.
- 4. The compound of claim 1, wherein R.sup.1 is hydrogen; R.sup.2 is hydrogen, halogen, amino, azido, or --OR.sup.7 (R.sup.7 is referred to as the same above); R.sup.3 and R.sup.4 is taken together form oxo.
- 5. The compound of claim 1, wherein R.sup.1 and R.sup.3 are both hydrogens; R.sup.2 and R.sup.4 are both hydrogens or halogens or R.sup.2 and R.sup.4 taken together form an unsaturated bond or --O--.
- 6. The compound of claim 1, wherein X is hydrogen, halogen, cyano, or methoxy.
- 7. The compound of claim 1, wherein R.sup.6 is hydrogen or cyano.
- 8. The compound of claim 1, wherein A is .dbd.NH; Y.sup.1 and Y.sup.2 taken together form oxo; R.sup.1, R.sup.3, R.sup.6, X, Z.sup.1 and Z.sup.2 are each hydrogens; R.sup.2 and R.sup.4 taken together form an unsaturated bond.
- 9. The compound of claim 1, wherein A is .dbd.NH; Y.sup.1 and Y.sup.2 taken together form oxo; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, X, Z.sup.1 and Z.sup.2 are each hydrogens.
- 10. A pharmaceutical composition containing the compound of claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9-067165 |
Mar 1997 |
JPX |
|
Parent Case Info
This application is a 371 of PCT/JP98/00992 filed Mar. 11, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/JP98/00992 |
3/11/1998 |
|
|
9/20/1999 |
9/20/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO98/42714 |
10/1/1998 |
|
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
6-239869 |
Aug 1994 |
JPX |
6-256350 |
Sep 1994 |
JPX |
7-145161 |
Jun 1995 |
JPX |
9711947 |
Apr 1997 |
WOX |